Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Nehal J. Lakhani, Arash Rezazadeh Kalebasty et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 140
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3John D. Powderly, Bartosz Chmielowski, Jan Baughman et al.|Journal for ImmunoTherapy of Cancer|2015Cited by 101